cell therapies

Allogene, broadening its reach, helps start a new biotech in China
Allogene, broadening its reach, helps start a new biotech in China
BioPharma Dive
Allogene
Overland Pharmaceuticals
China
cell therapies
Allogene Overland Pharma
Flag link:
AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients
AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients
Xconomy
AlloVir
IPOs
cell therapies
organ transplant
Flag link:
Bayer-backed Century buys Empirica to create brain cancer CAR-Ts
Bayer-backed Century buys Empirica to create brain cancer CAR-Ts
Fierce Biotech
Century Therapeutics
Empirica
cell therapies
brain cancer
glioblastoma
CAR-T
Flag link:
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
BioPharma Dive
Legend Biotech
IPOs
cancer
cell therapies
ASCO 2020
Flag link:
J&J inks Fate deal to move into allogeneic CAR therapies
J&J inks Fate deal to move into allogeneic CAR therapies
Fierce Biotech
JNJ
Fate Therapeutics
CAR NK
CAR-T
cell therapies
drug development
Flag link:
GSK pays $50M for 2 solid tumor cell therapies from Immatics
GSK pays $50M for 2 solid tumor cell therapies from Immatics
Pharmaceutical Business Review
GSK
solid tumors
cell therapies
Immatics
Flag link:
Myeloma cell therapies, now in pharma hands, move into spotlight
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
Flag link:
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Xconomy
Celgene
cell therapies
drug development
Immatics
cancer
Flag link:
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
lymphoma
Gilead Siences
Novartis
cell therapies
Kymriah
Yescarta
Flag link:
Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system
Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system
Endpoints
Sana Biotechnology
CAR-T
cell therapies
Harvard
Flag link:
Pluristem’s cell therapies head for orbit with NASA deal
Pluristem’s cell therapies head for orbit with NASA deal
Fierce Biotech
Pluristem
NASA
cell therapies
Flag link:
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Drug Delivery Business News
Eli Lilly
Sigilon
cell therapies
drug development
type 1 diabetes
Flag link: